Comparative Pharmacology
Head-to-head clinical analysis: FLUOXYMESTERONE versus TESTOPEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOXYMESTERONE versus TESTOPEL.
FLUOXYMESTERONE vs TESTOPEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic androgen receptor agonist; binds to androgen receptors, modulating gene expression and promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
Testosterone is an androgen receptor agonist; it binds to and activates androgen receptors, leading to changes in gene expression that promote male sexual development, maintenance of secondary sexual characteristics, and anabolic effects.
Adults: 5-20 mg orally once daily. For replacement therapy, 5-10 mg daily; for hypogonadism, 5-20 mg daily for several months.
Subcutaneous implantation: 150-450 mg every 3-6 months. Individualize based on serum testosterone levels and clinical response.
None Documented
None Documented
Clinical Note
moderateAcarbose + Fluoxymesterone
"Acarbose may increase the hypoglycemic activities of Fluoxymesterone."
Clinical Note
moderateSunitinib + Fluoxymesterone
"Sunitinib may increase the hypoglycemic activities of Fluoxymesterone."
Clinical Note
moderatePrednisolone + Fluoxymesterone
"Prednisolone may increase the fluid retaining activities of Fluoxymesterone."
Clinical Note
moderateDexamethasone + Fluoxymesterone
Terminal elimination half-life: 9.2 hours; clinical context: supports once-daily dosing for androgen replacement, with steady-state achieved in ~2 days
Terminal half-life: 8-10 days; due to prolonged release from subcutaneous depot, effective half-life extends to 2-3 weeks.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%
Renal: ~90% as glucuronide and sulfate conjugates, ~10% unchanged; fecal: ~6% via biliary elimination.
Category C
Category C
Androgen
Androgen
"Dexamethasone may increase the fluid retaining activities of Fluoxymesterone."